---
schema_version: "secwatch.filing_event.v1"
accession: "0001193805-23-001328"
form_type: "8-K"
ticker: "ARCT"
cik: "0001768224"
company_name: "Arcturus Therapeutics Holdings Inc."
filed_at: "2023-09-26T23:59:59+00:00"
generated_at: "2026-06-10T08:46:31.241016+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Arcturus extends CF Foundation deal; total funding up to ~$25M for ARCT-032 CF program

## Summary
- CF Foundation increases financial commitment to ~$25M to advance ARCT-032, an mRNA therapeutic for cystic fibrosis.
- Arcturus to provide $15M in matching funds; royalty rates and caps modified with option to reduce via one-time payment.
- Agreement extends prior program initiated in 2017; Phase 1b study in adults with CF planned imminently.
- ARCT-032 is mutation-agnostic and aims to express functional CFTR protein in the lung, addressing root cause of CF.

## SEC filing metadata
- accession: 0001193805-23-001328
- form_type: 8-K
- ticker: ARCT
- cik: 0001768224
- company_name: Arcturus Therapeutics Holdings Inc.
- filed_at: 2023-09-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1768224/000119380523001328/0001193805-23-001328-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1768224/000119380523001328/e618944_8k-arct.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193805-23-001328
- JSON: https://secwatch.observer/filing/0001193805-23-001328.json
- Plain text: https://secwatch.observer/filing/0001193805-23-001328.txt

## Key facts
- Material Agreements
  Arcturus Therapeutics Holdings Inc. amended the "Amendment" with Cystic Fibrosis Foundation valued at up to $9 million (effective 2023-09-25).
  - Action: amendment
  - Agreement: collaboration
  - Counterparty: Cystic Fibrosis Foundation
  - Value: up to $9 million
  - Effective: 2023-09-25
  source text: On September 25, 2023, Arcturus Therapeutics, Inc. (" Arcturus "), a subsidiary of Arcturus Therapeutics Holdings Inc. (the " Company "), entered into an amendment (the " Amendment ") to its Development Program Letter Agreement of May 16, 2017
  evidence_url: https://www.sec.gov/Archives/edgar/data/1768224/000119380523001328/0001193805-23-001328-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.